Hartz, Kuhn, Bentler, Levine, and London (1999) studied patient characteristics of 199 subjects with chronic fatigue. Subjects were at least 18 years of age and suffered from fatigue for at least 6 months. Idiopathic chronic fatigue was distinguished from CFS; patients with baseline characteristics that were similar to CFS demonstrated less fatigue improvement. Patients with less unclear thinking, less somatoform symptoms, and infrequent awakening showed more fatigue improvement.
Research (Jeffcoate, 1999) has not reached a consensus regarding fatigue found in patients with myalgic encephalitis (ME) and CFS. Because those with ME or CFS may suffer from cortisol deficiency, resulting in fatigue and other symptoms, hydrocortisone has been used for treatment of both. In a study of 32 CFS patients, scores for fatigue levels fell to normal levels in nine subjects (Jeffcoate). Research studies using Chalder et al.Ęs Fatigue Scale were not found. Studies regarding chronic fatigue agreed that the type of fatigue associated with CSF was unique to this disease. Brain abnormalities have been demonstrated for CFS patients and other sources of fatigue are ruled out for a CFS diagnosos. Confusion still exists, however, regarding differences in fatigue for ME and CFS.
Davis (1989) stated that the C-1 esterase inhibitor was the only plasma protease inhibitor of activated C-1r and C-1s, the serine protease subcomponents of the first complement component. Davis indicated that the C-1 esterase inhibitor was also the major inhibitor of plasma kallikrein and of coagulation factor XIIa. The C-1 esterase inhibitor consists of a single polypeptide chain of 478 amino acid residues, and is the most heavily glycosylated plasma protein.
Beck, A. T., & Beck, R. W. (1972 December). Screening depressed patients in family practice: A rapid technique. Postgraduate Medicine, 81-85.